Intarcia 'on cloud nine' after $210m private funding for once-yearly exenatide implant
This article was originally published in Scrip
Executive Summary
Intarcia Therapeutics raised a whopping $210 million in private financing in concurrent transactions to fund Phase III development of its type 2 diabetes product candidate ITCA 650, which consists of the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide delivered continuously by a matchstick-sized, subcutaneously-implanted osmotic pump.
You may also be interested in...
Drug Rejection Hearings Are Having A Moment At US FDA
With Intarcia's request, the rarely used mechanism could now produce two hearings this year, but outcomes of the few other times the process has been undertaken should not generate a lot of confidence for sponsors that this a path that they want to go down.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.